Ipamorelin vs Sermorelin: Mechanism, Dosing, Tracking

What Are GH Secretagogues?

A growth hormone secretagogue is any compound that signals the pituitary gland to secrete more of its own growth hormone. This is fundamentally different from injecting recombinant human growth hormone (rHGH or somatropin), where exogenous GH is added directly to the bloodstream. With secretagogues, the body remains in control of how much GH is ultimately released, and the natural pulsatile rhythm is preserved.

There are two broad categories of GH secretagogues most peptide users encounter:

GHRH analogs — These mimic growth hormone-releasing hormone (GHRH), the hypothalamic peptide that signals the pituitary through the GHRH receptor. Sermorelin is the classic example. CJC-1295 (with or without DAC), tesamorelin, and modified GRF 1-29 are all in this family. They tell the pituitary to release a GH pulse through the natural upstream signaling pathway.

GHRPs (Growth Hormone Releasing Peptides) / Ghrelin Mimetics — These bind the ghrelin receptor (GHS-R1a), which is a separate pathway that also triggers GH release and amplifies the GHRH signal. Ipamorelin, GHRP-2, GHRP-6, hexarelin, and ibutamoren (MK-677, an oral) all act here.

The reason GHRH analogs and GHRPs are often discussed together — and stacked together — is that they hit different receptors and produce a synergistic GH pulse when combined. A GHRH analog "primes" the pituitary, and a GHRP "amplifies" the pulse. This is the rationale behind the well-known CJC-1295 plus ipamorelin stack.

Both classes preserve negative feedback loops. If your IGF-1 climbs too high, somatostatin rises and dampens the GH response. That self-regulation is part of why secretagogues are favored over direct rHGH for many tracking-oriented protocols.

Ipamorelin Profile

Ipamorelin is a pentapeptide (five amino acids) developed in the late 1990s by Novo Nordisk as part of the search for a selective GH secretagogue. Its key characteristic — and the entire reason it dominates the GHRP conversation — is selectivity.

Mechanism. Ipamorelin is a selective agonist at the ghrelin receptor (GHS-R1a). Unlike GHRP-2 and GHRP-6, it does not meaningfully bind receptors that produce hunger spikes, prolactin elevation, or cortisol release. That cleaner profile is why it became the default GHRP in optimization protocols.

Half-life. Approximately 2 hours in serum. The biologically active window is short — peak GH release happens within 15 to 30 minutes of subcutaneous injection and tapers off within 60 to 90 minutes. This is why ipamorelin is typically dosed multiple times per day rather than once.

Typical dosing. Most published research and protocol references describe ipamorelin in the 100 to 300 mcg range per dose, administered subcutaneously. Multiple-dose-per-day protocols (often 2 to 3 times daily, including pre-bed to align with the natural overnight GH pulse) are common in optimization circles. Once-daily protocols exist but tend to underperform on IGF-1 response in tracking data because they miss the body's natural pulsatility.

Common protocols. Pre-bed monotherapy (200 mcg subcutaneous, 30 to 60 minutes before sleep, on an empty stomach), 3-times-daily pulsed dosing (100 to 200 mcg morning / mid-day / pre-bed), and stacked with a GHRH analog are the three patterns you will see most often.

What it does not do. Ipamorelin's selling point is the absence of cortisol and prolactin spikes that earlier GHRPs caused. It also does not significantly increase appetite (unlike GHRP-6, which is sometimes used specifically for that effect). For tracking-focused users who do not want collateral hormonal noise, this matters because it keeps your blood work readable — fewer confounding signals on cortisol or prolactin panels.

Sermorelin Profile

Sermorelin is a 29-amino-acid peptide that represents the first 29 amino acids of natural GHRH. It is the GHRH analog with the longest clinical history of the GH secretagogues most peptide users discuss today.

Mechanism. Sermorelin binds the GHRH receptor on pituitary somatotrophs (the cells that produce growth hormone). This triggers GH release through the natural upstream pathway — the same one your hypothalamus uses every day. Because it works through the GHRH receptor and not the ghrelin receptor, it does not raise cortisol or prolactin and does not affect appetite.

Half-life. Roughly 10 to 20 minutes in serum. This is shorter than ipamorelin and substantially shorter than CJC-1295 with DAC (which lasts about 7 days). The short half-life is intentional — it produces a clean, time-limited GH pulse that mimics endogenous GHRH release.

Typical dosing. Sermorelin is most often dosed in the 100 to 500 mcg range per administration, usually pre-bed to align with the natural overnight GH pulse window. Some protocols use higher per-dose amounts (up to 1 mg) less frequently. Daily subcutaneous injection is the most common pattern, though some clinics use 5-on, 2-off cycling to preserve receptor sensitivity.

FDA history. Sermorelin was FDA-approved in 1997 under the brand name Geref for diagnostic use and for pediatric growth hormone deficiency. The branded product was discontinued in 2008 for commercial reasons, not safety reasons. It is now most commonly accessed as a compounded peptide through 503A and 503B pharmacies in the United States. This regulatory history is part of why sermorelin is often the first GH secretagogue clinics offer — it has the clearest paper trail.

What makes it different. Compared to ipamorelin, sermorelin produces a more physiologic pulse pattern (it uses the natural GHRH pathway). It is generally considered the safer-feeling entry point for users new to GH secretagogues, which is partly why most clinics introduce it before ipamorelin. The trade-off is that the GH pulse is typically smaller per dose than what an equivalent ipamorelin pulse delivers.

Side-by-Side: Mechanism + Dosing

|---|---|---|

The two most consequential rows are half-life and frequency. Sermorelin's shorter half-life pushes most users to a single pre-bed dose; ipamorelin's longer half-life and clean side-effect profile makes 2-to-3-times-daily protocols feasible without stacking up cortisol or prolactin issues.

Stacking, Cycling, and Combination Protocols

The most common combination in the optimization community is a GHRH analog plus a GHRP. The textbook example is CJC-1295 (no DAC, also called modified GRF 1-29) stacked with ipamorelin, dosed together pre-bed and sometimes a second time mid-day. The rationale: CJC-1295 hits the GHRH receptor while ipamorelin hits the ghrelin receptor, producing a larger combined GH pulse than either peptide alone.

Sermorelin can substitute for CJC-1295 in this stack. A sermorelin plus ipamorelin protocol gives you the same dual-pathway activation, but with a shorter sermorelin half-life that some prescribers prefer for users sensitive to longer-acting compounds. The dose ranges are similar to monotherapy on each.

Stacking ipamorelin with sermorelin is less common because both can be combined more powerfully with their natural counterparts (CJC-1295 for ipamorelin; or ipamorelin for sermorelin, depending on which side you start from). But the combination is not unheard of.

Cycling conventions vary. Some users run continuous protocols and rely on regular IGF-1 monitoring to confirm receptor sensitivity is preserved; others run 5-on, 2-off weekly cycles or 8-to-12-week cycles with 2-to-4-week breaks. There is no consensus optimal cycle in the published literature, which is why provider input and trackable bloodwork matter more than rules-of-thumb.

What you log matters more than what you cycle. In MyProtocolStack, the dose, time, peptide, route, vial concentration, and reconstitution date all live on the same record — so if you are running a stack, the platform shows you the full picture instead of fragmented entries.

What Blood Markers to Track

This is the section most ipamorelin-vs-sermorelin articles skip entirely. If you are running either peptide, the blood work tells you whether the protocol is doing anything measurable — and whether anything else is shifting that should not be.

IGF-1 (Insulin-like Growth Factor 1) — The single most important biomarker for any GH secretagogue protocol. GH itself is pulsatile and impossible to interpret from a single blood draw, but IGF-1 is the downstream marker the liver produces in response to GH and stays relatively stable over the day. Track it at baseline, then every 4 to 8 weeks. Critical timing rule: draw IGF-1 fasted, in the morning, 24 to 36 hours after your last secretagogue dose. This captures trough rather than acute peak, which is the comparable number across visits. If you draw 4 hours after a dose, the result is meaningless for trend tracking.

IGFBP-3 (IGF Binding Protein 3) — IGF-1 circulates bound to IGFBP-3. Tracking the IGF-1/IGFBP-3 ratio gives a fuller picture than IGF-1 alone, particularly because IGFBP-3 also responds to GH stimulation. Most reference labs offer it as an add-on.

Fasting glucose and HbA1c — GH and IGF-1 both influence insulin sensitivity. Even at modest doses, some users see fasting glucose drift up by 5 to 10 mg/dL over a multi-month protocol. HbA1c is the slower-moving confirmation; check at baseline and every 3 months.

ALT/AST (liver enzymes) — IGF-1 is liver-produced. Sustained elevation of GH signaling sometimes shifts liver enzymes. Routine quarterly liver panels are reasonable on any chronic GH secretagogue protocol.

Prolactin — Particularly relevant if you are taking ipamorelin (a ghrelin-class peptide) and want to confirm the published "no prolactin spike" profile holds for you specifically. Baseline plus an 8-to-12-week recheck is sufficient for most users.

Cortisol baseline — Same logic. Ipamorelin's clean profile is well-established, but individual responses vary, and an AM cortisol every 6 months on a chronic protocol is a reasonable ask.

In MyProtocolStack, every IGF-1 result is logged with a `time_since_last_dose` field for exactly this reason — comparing two IGF-1 values drawn at different times relative to dosing is one of the most common mistakes in tracking GH secretagogue protocols.

Cost + Sourcing

Pricing for both peptides varies widely by source and quantity, but the general market shape in 2026 looks like this: research-grade ipamorelin tends to land in a similar per-milligram range as research-grade sermorelin, with both significantly cheaper per milligram than rHGH.

Cost-per-dose, however, depends on your protocol. A 200 mcg ipamorelin dose at typical pricing runs a few dollars; a 300 mcg sermorelin dose runs in a similar range. If you are dosing ipamorelin three times daily versus sermorelin once daily, monthly cost comparisons will favor sermorelin even at similar per-mg pricing.

Sermorelin is more often available through compounding pharmacies (503A in the US) on a prescription basis, which adds a clinical relationship to the cost stack but also adds quality assurance. Ipamorelin is most often accessed as a research peptide. Both peptide profile pages at <a href="/peptides/ipamorelin">/peptides/ipamorelin</a> and <a href="/peptides/sermorelin">/peptides/sermorelin</a> include sourcing considerations without naming specific pharmacies.

FAQ

Is ipamorelin or sermorelin stronger?

Ipamorelin typically produces a larger single-pulse GH release because it acts on the ghrelin receptor, while sermorelin produces a more physiologic pulse through the GHRH pathway. Stronger is not always better — sermorelin's pulse pattern more closely mimics the body's natural rhythm. Trackable IGF-1 response is the practical comparison most users actually monitor.

Can you stack ipamorelin and sermorelin together?

Many users combine a GHRH analog (sermorelin or CJC-1295) with a GHRP (ipamorelin) because they act on separate receptors and produce synergistic GH release. The most common stack is CJC-1295 (no DAC) plus ipamorelin. Always discuss any stack with your prescribing provider.

How long until I see IGF-1 changes on ipamorelin or sermorelin?

Most protocols show measurable IGF-1 shifts within 4 to 8 weeks. Always draw IGF-1 fasted, in the morning, 24 to 36 hours after the last dose to capture trough rather than peak. Logging the time-since-dose alongside the result is essential.

Does ipamorelin or sermorelin cause more side effects?

Sermorelin's side effect profile is well-characterized from its FDA history (mild flushing, injection-site reactions). Ipamorelin is favored among GHRPs specifically because it does not meaningfully raise cortisol or prolactin, unlike GHRP-2 or GHRP-6. Both are still investigational outside specific approved indications.

Which is cheaper, ipamorelin or sermorelin?

Pricing varies by source and quantity, but compounded sermorelin from 503A pharmacies is often comparable to or slightly more expensive than research-grade ipamorelin per milligram. Cost-per-dose differs because typical dosing differs (ipamorelin 100-300 mcg vs sermorelin 100-500 mcg).

Run the Numbers and Track the Response

The honest answer to "ipamorelin vs sermorelin" is that they are different tools for different protocol shapes — and the only way to know which one is doing what for you specifically is to dose-calculate accurately and track IGF-1 against time-since-dose.

Run side-by-side dose math with the <a href="/calculators/ipamorelin">ipamorelin calculator</a> and <a href="/calculators/sermorelin">sermorelin calculator</a>. Both let you input vial size, BAC water volume, and target dose to get insulin-syringe units in seconds. Read the full peptide profiles at <a href="/peptides/ipamorelin">/peptides/ipamorelin</a> and <a href="/peptides/sermorelin">/peptides/sermorelin</a>.

When you are ready to log doses against your IGF-1 trend over the coming months, <a href="/auth/login">create a free MyProtocolStack account</a> and start tracking from your next blood draw.

This article is for informational and educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting, adjusting, or stopping any peptide protocol. MyProtocolStack is a protocol tracking and blood work analysis platform — it is not a medical device and does not provide clinical recommendations.